latest news in companies
Loar Holdings Expands Aerospace Portfolio with $250 Million Acquisition of Harper Engineering
New York, Thursday, 22 January 2026.
Loar finalized this $250 million cash deal today, securing key aircraft interior technologies and projecting approximately $30 million in tax benefits from the strategic transaction.
USA Rare Earth Engages Fluor and WSP to Accelerate Texas Critical Minerals Production
Stillwater, Thursday, 22 January 2026.
Selecting Fluor and WSP to lead construction, USA Rare Earth targets an accelerated late 2028 production start for the strategic Round Top deposit, vital for domestic technology and defense.
Immuron Confirmed as Buy Opportunity Following Strong First-Half Revenue Data
New York, Thursday, 22 January 2026.
Emerging Growth Research has maintained a ‘Buy-Extended’ rating for Immuron Limited, reaffirming a $3.50 price target as of January 22, 2026. This positive outlook is underpinned by tangible financial performance, specifically a 5% increase in global revenue to AUD$4.2 million for the half-year ending December 31, 2025. Crucially, the analysis highlights a 17% revenue surge in the United States and a 13% increase in Australia, driven by robust demand for the company’s flagship travel health supplement, Travelan®. This commercial momentum, further bolstered by the December 2025 launch of the digestive health product ProIBS®, supports the valuation despite standard biopharmaceutical capital risks.
French Telecom Rivals Confirm Joint Talks to Acquire Altice Assets
Paris, Thursday, 22 January 2026.
On January 22, 2026, competitors Bouygues, Free, and Orange confirmed an unusual joint bid to acquire Altice’s French telecom assets, initiating due diligence for a potentially market-altering transaction.
Johnson & Johnson Faces New Legal Pressure as Judge Admits Cancer Evidence
New Brunswick, Thursday, 22 January 2026.
A special master’s recommendation now permits expert testimony linking talc to ovarian cancer, a critical procedural shift affecting over 67,500 lawsuits despite Johnson & Johnson’s immediate appeal plans.
Axogen Upsizes Stock Offering to $124 Million to Clear Debt and Fund Growth
Tampa, Thursday, 22 January 2026.
Axogen, Inc. has significantly expanded its capital raising targets, pricing an upsized public offering at $124 million—far exceeding the initially proposed $85 million. The biotechnology leader in peripheral nerve repair priced 4 million shares at $31.00 each, aiming to utilize the proceeds for the early repayment of its Oberland Capital debt and to fund general corporate growth. While this substantial capital injection streamlines the company’s balance sheet, the immediate market response saw shares slip in after-hours trading. This financing follows the company’s recent FDA approval for its Avance nerve graft, signaling a strategic pivot toward aggressive operational scaling despite short-term stock volatility.
